Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

Download as PDF

TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting at the American Peptide Symposium on their novel peptide synthesis platform for its lantibiotic pipeline.

The presentation is scheduled on Wednesday, June 26, 2019, at the American Peptide Symposium in the Sierra Ballroom of the Monterey Conference Center in Monterey, Calif. Presented by Dr. Jae H. Park, this work demonstrates the peptide synthesis platform developed using orthogonally-protected lanthionine building blocks. Following a description of the peptide synthesis, this work confirms the compound’s anti-microbial activity against Staphylococcus aureus. This novel synthetic approach will allow the synthesis of a wide array of novel Mutacin 1140 analogs, creating multiple new therapeutic opportunities for both Gram-positive and Gram-negative indications.

“We continue to see confirmation of anti-microbial activity with our Mutacin 1140 pipeline, and are pleased to continue to demonstrate its utility,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. “The need for new approaches to fighting antibiotic-resistant infections remains top of mind among medical professionals, and we are grateful that prestigious professional organizations continue to recognize this potential and we will continue to pursue the development of our lantibiotic programs. We look forward to continuing to provide updates on our progress.”

About Lantibiotics

Lantibiotics are a class of antibiotic compounds with novel mechanism of action, prized for their ability to overcome antibiotic-resistant infections. With resistant strains on the rise, particularly healthcare-acquired infections (HAI), the need for these potent lantibiotic agents is critical. Oragenics is pursuing the commercial-scale production of a lantibiotic for use as an antimicrobial.

About Oragenics, Inc.

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.

For more information about Oragenics, please visit www.oragenics.com.

Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission. Oragenics assumes no responsibility to update any forward-looking statements contained in this press release or with respect to the matters described herein.

Oragenics, Inc.
Corporate:
Michael Sullivan, 813-286-7900
Chief Financial Officer
msullivan@oragenics.com
or
Investors:
John Marco
Managing Director
CORE IR
310-819-2948
johnm@coreir.com
Media:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com

Source: Oragenics, Inc.

Released June 25, 2019